Comparing Selecta Biosciences (SELB) and Its Competitors

Selecta Biosciences (NASDAQ: SELB) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Selecta Biosciences to similar companies based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership.

Valuation & Earnings

This table compares Selecta Biosciences and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Selecta Biosciences $8.08 million -$36.21 million -2.90
Selecta Biosciences Competitors $290.27 million $35.99 million 54.72

Selecta Biosciences’ rivals have higher revenue and earnings than Selecta Biosciences. Selecta Biosciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings for Selecta Biosciences and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Selecta Biosciences 0 0 2 0 3.00
Selecta Biosciences Competitors 949 3403 11904 239 2.69

Selecta Biosciences presently has a consensus target price of $29.00, indicating a potential upside of 222.94%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.55%. Given Selecta Biosciences’ stronger consensus rating and higher possible upside, research analysts clearly believe Selecta Biosciences is more favorable than its rivals.


This table compares Selecta Biosciences and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Selecta Biosciences -1,918.59% -100.06% -61.41%
Selecta Biosciences Competitors -5,322.24% -84.37% -35.66%

Insider & Institutional Ownership

54.4% of Selecta Biosciences shares are held by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 41.9% of Selecta Biosciences shares are held by company insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company’s lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.

What are top analysts saying about Selecta Biosciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Selecta Biosciences and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit